Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma

Indian Journal of Cancer

Volumn 44, Issue 2, 2007, Pages 72-86

  Iqbal, Javeed ^a   Joshi, Shantaram ^a   Patel, Kavita N ^a   Javed, Sofi I ^a   Kucuk, Can ^a   Aabida, Afeera ^a   D'Amore, Francesco ^b   Fu, Kai ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Classification; Diffuse large B cell lymphomas; Gene expression profiling; Prognosis; Targeted therapy

Indexed keywords

EID: 35448995311     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509x.35814     Document Type: Article

References (103)

1. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000;96:808-22.
2. Gottesfeld JM, Wolf VJ, Dang T, Forbes DJ, Hartl P. Mitotic repression of RNA polymerase III transcription in vitro mediated by phosphrylatlon of a TFIIIB component. Science 1994;263:81-4.
3. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999;93:3601-9.
4. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Küppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-6.
5. Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003;101:2914-23.
6. Pasqualucci L, Bereschenko O, Niu H, Klein U, Basso K, Guglielmino R, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk Lymphoma 2003;44:S5-12.
7. Sanchez-lzquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, Karran L, et al. MALT 1 is deregulated by both chromosomal translocation and amplification In B-cell non-Hodgkin lymphoma. Blood 2003;101:4539-46.
8. Mao JH, Wu D, Perez-Losada J, Nagase H, DelRosario R, Balmain A. Genetic interactions between Pten and p53 In radiation-induced lymphoma development. Oncogene 2003;22:8379-85.
9. Wessendorf S, Schwaenen C, Kohlhammer H, Klenle D, Wrobel G, BarthTF, et al. Hidden gene amplifications in aggressive B-cell non-Hodgkln lymphomas detected by microarray-based comparative genomic hybridization. Oncogene 2003;22:1425-9.
10. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992;79:2701-7.
11. Greiner TC, Gascoyne RD, Anderson ME, Kingma DW, Adomat SA, Said J, et al. Nodular lymphocyte-predominant Hodgkln's disease associated with large-cell lymphoma: Analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 1996;88:657-66.
12. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson J R, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87:4302-10.
13. Gronbaek K, de Nully Brown P, Møller MB, Nedergaard T, Ralfkiaer E, Mailer P, et al. Concurrent disruption of p 161N K4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000;14:1727-35.
14. Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997;89:272-80.
15. Sanchez-Beato M, Sáez Al, Navas IC, Algara P, Sol Mateo M, Villuendas R, et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations In p53, p16, and p27. AmJ Pathol 2001;159:205-13.
16. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression In follicular lymphomas. Blood 1993;82:1994-2004.
17. Lo Coco F, Galdano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993;82:2289-95.
18. Cahir-McFarland ED, Carter K, Rosenwald A, GiltnaneJM, Henrickson SE, Staudt LM, et al. Role of NF-kappa B In cell survival and transcription of latent membrane protein-1-expressing or Epstein-Barr virus latency-ill-infected cells. J Virol 2004;78:4108-19.
19. Hosokawa Y, Suzuki H, Suzuki Y, Takahashi R, Seto M. Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma. Cancer Res 2004;64:3452-7.
20. Poppema S, Magglo E, van den Berg A. Development of lymphoma in autoimmune lymphoproliferatlve syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma 2004;45:423-31.
21. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C, et al. In vivo activation of STAT3 In cutaneous T-cell lymphoma: Evidence foran antiapoptotic function of STAT3. Leukemia 2004;18:1288-95.
22. Nakayama K, Kamihira S. Survivin an important determinant for prognosis In adult T-cell leukemia: A novel biomarker in practical hemato-oncology. Leuk Lymphoma 2002;43:2249-55.
23. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74.
24. Davis JE, Smyth MJ, Trapani JA. Granzyme A- and B-deficient killer lymphocytes are defective In eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur J Immunol 2001;31:39-47.
25. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
26. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B-cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-62.
27. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
28. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival In mantle cell lymphoma. Cancer Cell 2003;3:185-97.
29. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Levai L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-9.
30. Shipp MA, Ross KN, Jamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
31. Rimsza LM, Roberts RA, MillerTP, Unger JM, LeBlanc M, Braziel RM, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251-8.
32. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival In follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
33. st edn. CA: Eaton Publishing; 2000. pp. 297.
34. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21:33-7.
35. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
36. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol 1999;303:179-205.
37. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage: The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-35.
38. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
39. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
40. Fu K, Iqbal J, Chan WC. Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma. Expert Rev Mol Diagn 2005;5:397-408.
41. Iqbal J, D'Amore F, Hu Q, Chan WC, Fu K. Current Hematologic Malignancy Reports 1, 129 (April, 2006).
42. Dybkaer K, Iqbal J, Zhou G, Chan WC. Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma. Clin Lymphoma 2004;5:19-28.
43. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, et al. Ongoing immunoglobulin somatic mutation In germinal center B-cell-like but not In activated B-cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000;97:10209-13.
44. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. AmJ Pathol 2004;165:159-66.
45. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, et al. The t(14; 18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;99:2285-90.
46. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961-8.
47. Swerdlow SH. In: Jaffe ES, Harris NL, Stein H, Vardlman JW, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp. 168-70.
48. Fang NY, Greiner TC, Weisenburger DD, Chan WC, Vose JM, Smith LM, et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations In the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA 2003;100:5372-7.
49. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW, et al. Altered apoptosis pathways In mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001;98:787-94.
50. Nathwani BN. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp. 162-7.
51. Lossos IS, Levy R. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. Blood 2000;96:635-9.
52. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996;88:3937-44.
53. Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL, et al. p 16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998;91:2977-84.
54. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p 16 and p15 are associated with histologic progression In follicle center lymphoma. Blood 1998;91:4677-85.
55. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
56. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-30.
57. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkltt's lymphoma. N Engl J Med 2006;354:2431-42.
58. Conconi A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab In extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-5.
59. Sah A, Barrens SL, Parapia LA, Jack AS, Owen RG. Cutaneous B-cell lymphoma: Pathological spectrum and clinical outcome in 51 consecutive patients. Am J Hematol 2004;75:195-9.
60. Hoefnagel JJ, Dljkman R, Basso K, Jansen PM, Hallermann C, Willemze R, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005;105:3671-8.
61. Rai KR, Wasil T, Iqbal U, Driscoll N, Patel D, Janson D, et al. Clinical staging and prognostic markers In chronic lymphocytic leukemia Hematol Oncol Clin North Am 2004;18:795-805.
62. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
63. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
64. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005;106:1189-98.
65. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
66. Fait S, Merup M, Tobin G, Thunberg U, Gahrton G, Rosenquist R, etal. Distinctive gene expression pattern In VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood 2005;106:681-9.
67. Dickinson JD, Smith LM, Sanger WG, Zhou G, Townley P, Lynch JC, et al. Unique gene expression and clinical characteristics are associated with the 11q23 deletion In chronic lymphocytic leukaemia. Br J Haematol 2005;128:460-71.
68. Haslinger C, Schweifer N, Stilgenbauer S, Döhner H, Lichter P, Kraut N, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004;22:3937-49.
69. Dickinson JD, Joshi A, Iqbal J, Sanger W, Bierman PJ, Joshi SS. Genomic abnormalities In chronic lymphocytic leukemia influence gene expression by a gene dosage effect. Int J Mol Med 2006;17:769-78.
70. Plate JM, Petersen KS, Buckingham L, Shahidl H, Schofield CM. Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis. Exp Hematol 2000;28:1214-24.
71. Stratowa C, Löffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, et al. cDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved In lymphocyte trafficking. Int J Cancer 2001;91:474-80.
72. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
73. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, et al. NF kappa B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392-9.
74. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61.
75. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1 Cell 1999;98:859-69.
76. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
77. Bea S, Tort F, Pinyol M, Puig X, Hernández L, Hernández S, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001;61:2409-12.
78. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
79. Dickinson JD, Gilmore J, Iqbal J, Sanger W, Lynch JC, Chan J, et al. 11q22.3 deletion In B-chronic lymphocytic leukemia Is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006;47:231-44.
80. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
81. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations In chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
82. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A microRNA signature associated with prognosis and progression In chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801.
83. Calin GA, Sevignani C, Dumitru CD, HyslopT, Noch E, Yendamuri S, etal. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.
84. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B-cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101:11755-60.
85. Calin GA, Croce CM. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 2006;66:7390-4.
86. D'Orazio D, Stumm M, Sieber C. Accurate gene expression measurement in formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2002;160:383-4.
87. Abrahamsen HN, Steiniche T, Nexo E, Hamilton-Dutoit SJ, Sorensen BS. Towards quantitative mRNA analysis In paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: A methodological study on lymph nodes from melanoma patients. J Mol Diagn 2003;5:34-41.
88. Godfrey TE, Kim SH, Chavira M, Ruff DW, Warren RS, Gray JW, et al. Quantitative mRNA expression analysisfrom formalin-fixed, paraffinembedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2000;2:84-91.
89. Koopmans M, Monroe SS, Coffield LM, Zaki SR. Optimization of extraction and PCR amplification of RNA extracts from paraffinembedded tissue in different fixatives. J Virol Methods 1993;43:189-204.
90. Ladanyi M, Cavalchire G, Morris SW, Downing J, Filippa DA. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation In Hodgkin's disease. Am J Pathol 1994;145:1296-300.
91. Hui P, Howe JG, Crouch J, Nimmakayalu M, Qumsiyeh MB, Tallini G, et al. Real-time quantitative RT-PCR of cyclin D1 mRNA In mantle cell lymphoma: Comparison with FISH and immunohistochemistry. Leuk Lymphoma 2003;44:1385-94.
92. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression In archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42.
93. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival In diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-37.
94. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
95. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003;101:433-40.
96. Pan Z, Shen Y, Du C, Zhou G, Rosenwald A, Staudt LM, et al. Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. Am J Pathol 2003;163:135-44.
97. Natkunam Y, Lossos IS, Taidi B, Zhao S, Lu X, Ding F, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005;105:3979-86.
98. Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1978;42:1705-10.
99. Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS, et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990;8:84-93.
100. Klimo P, Connors JM. MACOP-B chemotherapy for the trea ment of diffuse large-cell lymphoma. Ann Intern Med 1985;102:596-602.
101. Klimo P, Connors JM. MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkln's disease. J Clin Oncol 1985;3:1174-82.
102. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
103. Elenitoba-Johnson KS, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z, et al. Involvement of multiple signaling pathways In follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100:7259-64.